Corporate ActionMay 8, 2026, 06:55 AM
Artiva Prices $300M Underwritten Offering of Common Stock & Warrants
AI Summary
Artiva Biotherapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten offering of common stock and pre-funded warrants. The offering includes 23,871,526 shares of common stock at $11.52 per share and 2,170,138 pre-funded warrants at $11.5199 per share. The company expects to raise approximately $300 million in gross proceeds from the offering, which saw participation from several institutional investors and is slated to close around May 11, 2026.
Key Highlights
- Artiva priced an underwritten offering of 23,871,526 common shares at $11.52 per share.
- The offering also included 2,170,138 pre-funded warrants at $11.5199 per share.
- Gross proceeds are expected to be approximately $300 million before deductions.
- The offering is anticipated to close on or about May 11, 2026.
- Key investors include Caligan Partners, Venrock, Adage, RA Capital, Viking, Samsara, EcoR1, Blackstone, GC Corporation, GC Cell, RTW, Blue Owl, and a Large Mutual Fund.
- Jefferies, TD Cowen, and Cantor are joint book-running managers for the offering.